ProMIS Neurosciences remains a high-risk, pre-revenue biotechnology entity heavily reliant on external financing to sustain its PMN310 clinical program. While the company focuses exclusively on R&D, the lack of commercial revenue and persistent operating losse...
Price trend, volume and key moving averages
Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$1.28+7.2% vs -$1.38 | — vs — |
Q2 2026 May 12, 2026 | -$1.26-18.9% vs -$1.06 | — vs — |
Q2 2026 May 11, 2026 | -$1.26-18.9% vs -$1.06 | — vs — |
Q2 2026 Mar 25, 2026 | -$4.11+11.8% vs -$4.66 | — vs — |
Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.
Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year.CF Revenue: Global CF revenue grew 11% year-over-year in Q2 2026.CASGEVY Revenue: $76 million in Q
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.
Benchmark PMN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ProMIS Neurosciences, Inc. (PMN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.35 | $17.46M | -0.59 | — | — | -521.61% | — | |
| $9.61 | $503.11M | -2.12 | -92.84% | -80.67% | -14.98% | — | |
| $9.28 | $598.76M | -7.25 | -0.3% | 2.94% | 1.91% | — | |
| $28.89 | $4.95B | 12.62 | 11.87% | 33.42% | 32.39% | — | |
| $0.94 | $45.26M | -1.80 | — | — | -95.77% | — | |
| $3.44 | $59.46M | -2.57 | — | -691.81% | — | — |
ProMIS Neurosciences, Inc. (PMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ProMIS Neurosciences, Inc. (PMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 28, 2026·SEC
May 20, 2026·SEC
Get notified when PMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ProMIS Neurosciences, Inc. (PMN) stock FAQ — growth, dividends, profitability & financials explained
ProMIS Neurosciences, Inc. (PMN) reported a net loss of $42.2M for fiscal year 2025.
ProMIS Neurosciences, Inc. (PMN) has a return on equity (ROE) of -521.6%. Negative ROE indicates the company is unprofitable.
ProMIS Neurosciences, Inc. (PMN) had negative free cash flow of $42.0M in fiscal year 2025, likely due to heavy capital investments.
